An RNA molecule contributes to therapy resistance of triple negative breast cancer

Triple-negative breast cancer (TNBC) is the most aggressive type of breast cancer. Chemotherapy before or after surgery remains the standard treatment regimen for stage I–III TNBC. Only a small portion of patients can benefit from targeted therapy with PARP inhibitors because of BRCA mutations. However, resistance to chemotherapy or targeted therapy remains a major hurdle.

≈